



Scientific Program as at 22 November 2018

Subject to change

Tuesday 27 November 2018

08:00 – 10:30	ASCEPT Board meeting		
	Room: L1B		
09:00 – 18:00	Registration desk open Foyer, Hall L and M		
10:30 – 16:45	Careers and Early Stage Biomedical Translation Workshop Part of the Accelerating Australia National Conference (10:30 – 16:45)	Pharmacogenomics Workshop (10:30 – 12:30)	Prescribing Safety Assessment Workshop incorporating Clinical Pharmacology Workshop (10:30 – 16:45)
	Room: Hall M	Room: L2	Room: L3
	Chair: Assoc Prof Kevin Pflieger	Chair: Prof Andrew Somogyi	Chair: Prof Sarah Hilmer
	10:30 – 12:15 Biomedical entrepreneurship How an entrepreneurial mindset can help you strategise for your future career	10:30 – 10:35 Welcome and introduction Prof Andrew Somogyi, Chair ASCEPT Pharmacogenomics SIG	10:30 – 11:15 Overview of the PSA and progress to date Assoc Prof Claire Harrison, Monash University
	12:15 – 12:45 Lunch	10:35 – 11:15 Aboriginal genomic diversity and pharmacogenetics Prof Alan Cooper, Australian Centre for Ancient DNA, University of Adelaide	11:15 – 11:30 ASCEPT and the PSA Prof Carl Kirkpatrick, Monash University
	12:45 – 14:30 Accelerating Australia early stage innovation showcase Pitches from Accelerating Australia course participants	11:15 – 11:35 Old drugs, new tricks: a “golden” opportunity for chemotherapy pharmacogenomics? Assoc Prof Nuala Helsby, University of Auckland, New Zealand	11:30 – 12:30 Timelines and infrastructure for 2019 and beyond Prof Sarah Hilmer, Royal North Shore Hospital and The University of Sydney; Assoc Prof Claire Harrison, Monash University and Assoc Prof Matt Doogue, University Of Otago, New Zealand
	14:30 – 15:00 Afternoon tea	11:35 – 11:50 Pharmacogenetics of immunosuppressant uptake in graft tissue of renal transplant recipients Assoc Prof Benedetta Sallustio, The Queen Elizabeth Hospital, Adelaide	12:30 – 13:30 Lunch (own expense)
	15:00 – 16:45 Working with industry Showcasing success stories from the current ecosystem	11:50 – 12:05 Pharmacogenetics in Papua New Guinea HIV/AIDS patients: an update Helena van Schalkwyk, University of Adelaide	13:30 – 14:15 PSA item creation Assoc Prof Claire Harrison, Monash University
	Supported by  	12:05 – 12:30 Pharmacogenomics SIG AGM	14:15 – 15:15 How do we teach clinical pharmacology? Can we collaborate?
		Education Forum (13:00 – 16:45)	15:15 – 15:30 AOB Prof Sarah Hilmer, Royal North Shore Hospital and The University of Sydney; Assoc Prof Claire Harrison, Monash University
	Room: L2		
	Chair: Assoc Prof Elizabeth Davis		

		<p>13:00 – 16:00 Hit the ground running... How do we embed WIL in our pharmacology programs?</p> <p>Guest speaker: Prof Janice Orrell, Flinders University</p> <p>16:00 – 16:45 Education Forum AGM</p>	<p>16:00 – 16:45 Clinical Pharmacology SIG AGM</p>
17:00 – 18:00	Conference opening and keynote address		
	<p>Room: Hall M</p> <p>Chair: Prof Carl Kirkpatrick and Assoc Prof Kevin Pflieger</p> <p>SPARKing translation of fundamental research to clinical impact - 100 Prof Daria Mochly-Rosen, School of Medicine, Stanford University, USA</p>		
18:00 – 19:30	<p>Welcome reception</p> <p>G030 Lecture Theatre, University of Adelaide Health and Medical Sciences Building, North Terrace</p>		<p>Supported by</p>  <p>the hospital research foundation finding cures improving care</p>

Wednesday 28 November 2018


07:30 – 18:00	<p>Registration desk open Foyer, Hall L and M</p>		
08:30 – 09:30	British Pharmacological Society keynote address		
	<p>Room: Hall M</p> <p>Chair: Prof Carl Kirkpatrick</p> <p>Measuring drug where it matters: The importance of micro-pharmacokinetics on observed receptor pharmacology - 101 Prof Steven Charlton, School of Life Sciences, University of Nottingham, UK</p>		
09:30 – 10:25	<p>Morning tea with exhibitors</p> <p>Poster presentations: Clinical Pharmacology, Drug Discovery, Education, Pharmacoepidemiology, Respiratory and Inflammation</p>		<p>Supported by</p> 
10:30 – 12:30	<p>Symposium 1: Novel mechanisms and targets in sensory pathways</p> <p>Room: Hall M</p> <p>Chairs: Dr Nicholas Veldhuis and Dr Luke Grundy</p>	<p>Symposium 2: Innovative targets and drug delivery systems for inflammatory diseases</p> <p>Room: L2</p> <p>Chairs: Prof Emilio Badoer and Prof Ross Vlahos</p>	<p>Symposium 3: Pharmacotherapies to delay ageing</p> <p>Room: L3</p> <p>Chairs: Assoc Prof Victoria Cogger and Dr Nicholas Hunt</p>
10:30 – 11:00	<p>Functional Divergence of Delta and Mu Opioid Receptor Organization in Pain Circuits - 102 Assist Prof Greg Scherrer, Stanford University, USA</p>	<p>Electroceuticals as innovative strategies to target inflammatory bowel disease - 106 Dr Martin Stebbing, Florey Institute of Neuroscience and Mental Health and The University of Melbourne</p>	<p>Ageing and caloric restriction research: A biological perspective with translational potential - 110 Assoc Prof Rozalyn Anderson, University of Wisconsin-Madison, USA</p> <p>Supported by</p> 
11:00 – 11:30	<p>CGRPα within the TRPV1-cre population contributes to visceral nociception - 103 Prof Nick Spencer, Flinders University</p>	<p>Endosome and mitochondrial reactive oxygen species as novel targets in respiratory infectious disease - 107 Dr Stavros Selemidis, RMIT University</p>	<p>Nutrition, aging and drug discovery - 111 Prof David Le Couteur, Concord Hospital and The University of Sydney</p>
11:30 – 12:00	<p>Using novel toxin peptides to understand peripheral pain mechanisms - 104 Dr Luke Grundy, The University of Adelaide</p>	<p>Angiotensin II Type 2 receptors as targets in inflammatory and fibrotic disease - 108 Prof Robert Widdop, Monash University</p>	<p>Pharmacologic manipulation of DNA repair and metabolism to extend lifespan and reproduction - 112 Dr Lindsay Wu, University of New South Wales</p>

12:00 – 12:30	Opioid receptor allosteric modulators for normalising receptor trafficking and gut motility - 105 Dr Daniel Poole, Monash Institute of Pharmaceutical Sciences, Monash University	Nanoparticles as delivery vehicles in inflammatory disease - 109 Dr Kirsty Wilson, RMIT University	Targeting the ageing liver microcirculation to prevent age related disease - 113 Assoc Prof Victoria Cogger, The University of Sydney
12:30 – 13:25	Lunch with exhibitors Poster presentations: Clinical Pharmacology, Drug Discovery, Education, Pharmacoepidemiology, Respiratory and Inflammation		Supported by  South Australian Health & Medical Research Institute
13:30 – 15:30	Oral presentations 1: Clinical Pharmacology/ Clinical Trainees	Oral presentations 2: Neuro- and Behavioural Pharmacology/Toxicology	Oral presentations 3: Cardiovascular Pharmacology
	Room: Hall M	Room: L2	Room: L3
	Chairs: Dr Peter Donovan and Dr Tilenka Tynne	Chairs: Dr Wendy Imlach and Dr Ian Musgrave	Chairs: Assoc Prof Jason Peart and Dr Antony Vinh
13:30 – 13:45	Improving the understanding of an old drug to treat the youngest patients: Population pharmacokinetics of pentoxifylline and its metabolites in critically ill, very pre-term infants - 114 Dr Sam Salman, The University of Western Australia	Investigating potential functional crosstalk of co-located metabotropic glutamate receptor 5 and adenosine A1 receptors in primary neurons and glia - 122 Miss Nguyen Hong Phuc Trinh, Monash Institute of Pharmaceutical Sciences, Monash University	The effect of long-term polypharmacy on cardiovascular functions and cardiac fibrosis in aged mice - 130 Ms Trang Tran, The University of Sydney
13:45 – 14:00	Association between drug burden index and geriatric syndromes in a large, single-centre general medicine cohort - 115 Dr Christopher McMaster, Austin Health	Does gabapentin or pregabalin directly modulate the Mu Opioid Receptor? - 123 Dr Bridin Murnion, The University of Sydney	Therapeutic role of rAAV6-BMP7 to limit diabetic cardiomyopathy in type 2 diabetic mice - 131 Miss Nimna Perera, Baker Heart and Diabetes Institute
14:00 – 14:15	Adalimumab exposure and pregnancy outcomes in women with inflammatory bowel disease: A systematic review and meta-analysis - 116 Dr Jessica Gehlert, Flinders Medical Centre	Lithium reverses mechanical allodynia through a mu opioid receptor-dependent mechanism - 124 Dr Yannick Goumon, University of Strasbourg, France	Investigating the therapeutic targeting of myofibroblast-inflammasome activity to treat cardiac fibrosis - 132 Mr Felipe Tapia Caceres, Monash University
14:15 – 14:30	Paracetamol for pain and fever: A systematic review of systematic reviews - 117 Dr Christina Abdel Shaheed, The University of Sydney	AE Succinimide, an analogue of Methyllycaconitine MLA stabilizes the closed state of the $\alpha 4\beta 2$ nAChR - 125 Mrs Taima Qudah, The University of Sydney	The single chain-derivative, B7-33, retains the cardioprotective effects of relaxin - 133 Assoc Prof Chrisan Samuel, Monash University
14:30 – 14:45	Adverse drug reactions to opioids in electronic health records: Implications for prescribing alerts - 118 Dr Joshua Inglis, Royal Adelaide Hospital	In vitro cytotoxic activity of natural products and derivatives in different nanoformulations against brain cancer cells - 126 Dr Rebecca Roubin, The University of Sydney	G protein-coupled estrogen receptors: Novel therapeutic targets in aldosterone/salt-induced hypertension? - 134 Dr Quynh Nhu Dinh, La Trobe University
14:45 – 15:00	Bayesian networking reveals links between toxicities, genetics and treatment parameters following 5-fluorouracil (5-FU)-based treatment - 119 Dr Janet Coller, The University of Adelaide	Betulinic acid derivatives protect Müller cells from glutamate-induced oxidative stress - 127 Miss Zhengqi Cheng, The University of Sydney	Relaxin mediates its anti-fibrotic actions in human cardiac myofibroblasts via AT2 receptor-dependent phosphatases - 135 Mr Chao Wang, Monash University
15:00 – 15:15	The effect of chronic polypharmacy, the Drug Burden Index (DBI) and deprescribing on physical function in aged mice - 120 Dr John Mach, The University of Sydney and Kolling Institute	The sources, distribution, human toxicity and pharmacologic effects of cannabis contaminants - 128 Dr Laura Dryburgh, Hunter Medical Research Institute	Multiple adenosine receptor subtypes stimulate wound healing in human EA.hy926 endothelial cells - 136 Assoc Prof Roselyn Rose'Meyer, Griffith University

15:15 – 15:30	Application of cytochrome P450 (CYP) phenotyping procedure in clinical setting: a feasibility study – 121 Dr Sussan Ghassabian, The University of Sydney	The effects of chronic polypharmacy and deprescribing on the livers of aged mice – 129 Miss Lydia Conti, The University of Sydney	Effects of cytokines, toll-like receptors and signal transduction receptor gene polymorphisms on acute rejection in kidney transplant patients – 137 Ms Rong Hu, The University of Adelaide
15:30 – 15:55	Afternoon tea with exhibitors		
	Supported by  	Toxicology SIG AGM Room: L2	Cardiovascular SIG AGM Room: L3
16:00 – 18:00	Oral presentations 4: Garth McQueen student oral prize/ Education Room: Hall M Chairs: Prof Dominic Geraghty and Dr Danijela Gnjidic	Oral presentations 5: Pharmacogenomics/ Clinical Pharmacology Room: L2 Chairs: Assoc Prof Nuala Helsby and Prof Andrew Somogyi	Oral presentations 6: Drug Discovery Room: L3 Chairs: Prof Stephen Hill and Dr Angela Finch
	16:00 – 16:15	Reducing inappropriate polypharmacy and deprescribing: An online education module for hospital clinicians – 138 Dr Brendan Ng, The University of Sydney	Is a genotype-phenotype relationship predictive of 5-fluorouracil-induced severe GI toxicity incidence? A pilot study. – 146 Miss Samantha Korver, The University of Adelaide
	16:15 – 16:30	Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: A systematic review and meta-analysis – 139 Dr Tamara Milder, St Vincent's Hospital	Yohimbine, a new phenotyping measure for CYP2D6 activity – 147 Prof Gerd Mikus, University Hospital Heidelberg, Germany
16:30 – 16:45	Predictive performance of a commercial bayesian forecasting program in estimating vancomycin drug exposure – 140 Ms Rashmi Shingde, St Vincent's Hospital	Failure to account for phenoconversion may lead to misleading pharmacogenomic (PGx) reports – 148 Mr Sam Mostafa, MyDNA Life Australia Limited and Monash University	A molecular ruler for ligand efficacy: Using NMR to probe ligand induced changes in α1A-adrenoceptor conformational equilibria and characterize fragment hits – 156 Dr Daniel Scott, Florey Institute of Neuroscience and Mental Health
16:45 – 17:00	Total and unbound mycophenolic acid pharmacokinetics before and after kidney transplantation – 141 Dr David Metz, The University of Melbourne	Genomic Guided Pharmacotherapy: A pilot study in danish patients suffering from chronic non-cancer pain – 149 Prof Lona Loring Christrup, University of Copenhagen, Denmark	Cryptic pocket formation underlies subtype selectivity at the M1 muscarinic Acetylcholine receptor (M1 mAChR) – 157 Dr Celine Valant, Monash Institute of Pharmaceutical Sciences, Monash University
17:00 – 17:15	Ebselen prevents cigarette smoke-induced endothelial-dependent dysfunction in mouse thoracic aorta – 142 Mr Kurt Brassington, RMIT University	Effect of chronic polypharmacy and the Drug Burden Index (DBI) on muscle function and structure in aged mice – 150 Miss Gizem Gemikonakli, The University of Sydney	Assessing adenosine A1 receptor-mediated G protein dissociation using a NanoBiT assay – 158 Miss Samantha McNeill, Monash Institute of Pharmaceutical Sciences, Monash University
17:15 – 17:30	Drugs used in pregnancy and neonatal medicine: How likely are they to access the developing brain? – 143 Mr Liam Koehn, The University of Melbourne	The role of UGT enzymes in cytotoxic drug resistance in breast cancer cells and cancer stem cells – 151 Mr Radwan Ansaar, Flinders University	Structural insights into the allosteric binding sites of the M5 muscarinic acetylcholine receptor – 159 Dr David Thal, Monash Institute of Pharmaceutical Sciences, Monash University
17:30 – 17:45	Novel AT2 receptor agonists reverse high salt diet-induced cardiac and renal fibrosis – 144 Mrs Yan Wang, Monash University	How are we using immunosuppressant medicines in Australasian elderly renal transplant recipients? – 152 Ms Amelia Cossart, The University of Queensland	Mechanistic pathways of metformin induced reversal of age-related pseudocapillarization in mice liver endothelium – 160 Dr Nicholas Hunt, Anzac Research Institute, The University of Sydney



17:45 – 18:00	Relationship between academic outcomes in a pharmacology unit of a biomedical science degree, and attending lectures or accessing lecture recordings: Is it detrimental to access lecture recordings? – 145 Dr Sheila Doggrell, Queensland University of Technology	Microsampling as an alternative collection method to venous blood to quantify capecitabine and its metabolites by LC-MS/MS – 153 Ms Mirjana Radovanovic, The University of Newcastle	Calcium imaging in organoids and ex vivo tissue: New insights into spontaneous and agonist-induced calcium responses – 161 Dr Felicity Davis, Mater Research Institute, The University of Queensland
18:30 – 19:15	Guided walking tour of the Garden of Health (optional, registration required) An iconic health and wellbeing demonstration garden displaying plants used to heal and promote wellbeing in western and nonwestern cultures.		
	Garden of Health, Adelaide Botanic Garden Meet at the Ginkgo Gate near Frome Road		


Thursday 29 November 2018

08:00 – 17:00	Registration desk open Foyer, Hall L and M		
08:30 – 09:00	Gillian Shenfield Early Educator Award		
	Room: Hall M	Supported by 	
	Chair: Assoc Prof Lynette Fernandes		
	Evaluating student perceptions of novel feedback methods – 200 Dr Klaudia Budzyn, Monash University		
09:00 – 09:30	Early Achievement Award for Women		
	Room: Hall M	Supported by 	
	Chair: Assoc Prof Tina Hinton		
	Evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine in people with dementia – 201 Dr Emily Reeve, The University of Sydney and Dalhousie University		
09:30 – 10:25	Morning tea with exhibitors		Supported by
	Poster presentations: Cardiovascular, Drug Disposition and Response, Neuro- and Behavioural Pharmacology, Pharmacogenomics, Toxicology, Urogenital and Gastrointestinal		 University of South Australia
10:30 – 12:30	Symposium 4: Opioid analgesia and tolerance: from bench to bedside	Symposium 5: Towards the clinic: innovation in urology and gastrointestinal therapies	Symposium 6: Novel cardiovascular drug discovery targets
	Room: Hall M	Room: L2	Room: L3
	Chairs: Dr Irina Vetter and A/Prof Marie-Odile Parat	Chairs: Dr Lu Liu and Dr Betty Exintaris	Chairs: Dr Karen Gregory and Prof Rebecca Ritchie
10:30 – 11:00	Spatial and temporal dimensions of MOR signalling: Implication for the development of tolerance – 202 Dr Michelle Halls, Monash Institute of Pharmaceutical Sciences, Monash University	Beneficial effects of prazosin treatment during radiotherapy for prostate cancer – 206 Dr David Christie, GenesisCare	Insulin regulated aminopeptidase – what is it and why should we target it in cardiovascular disease? – 210 Dr Tracey Gaspari, Monash University
11:00 – 11:30	Cellular mechanisms of opioid tolerance and dependence – 203 Prof Mac Christie, The University of Sydney	Therapeutic potential of medical cannabis in gastrointestinal disorders – 207 Dr Scott Smid, The University of Adelaide	Disease-specific context of biased agonism and its application for cardiovascular disease – 211 Dr Paul White, Monash Institute of Pharmaceutical Sciences, Monash University
11:30 – 12:00	Neuroimmune genetics of acute postoperative pain and opioid analgesia – 204 Dr Daniel Barratt, The University of Adelaide	Non-hormonal male contraception using a combination of adrenoceptor and purinoceptor antagonists – 208 Dr Sab Ventura, Monash Institute of Pharmaceutical Sciences, Monash University	Exploiting biased agonism for managing cardiac ischaemia – 212 Dr Helena Qin, Baker Heart and Diabetes Institute

12:00 – 12:30	Non-opioid receptor-mediated actions of opioids: Preclinical and clinical studies – 205 A/Prof Marie-Odile Parat, The University of Queensland	Towards a personalised approach for the treatment of BPH – 209 Dr Betty Exintaris, Monash Institute of Pharmaceutical Sciences, Monash University	Orphan GPCRs in cardiovascular disease – 213 Dr James Coleman, Victor Chang Cardiac Research Institute
12:30 – 13:25	Lunch with exhibitors Poster presentations: Cardiovascular, Drug Disposition and Response, Neuro- and Behavioural Pharmacology, Pharmacogenomics, Toxicology, Urogenital and Gastrointestinal		Supported by 
13:30 – 15:30	Certara New Investigator Award Room: Hall M Chair: Prof Carl Kirkpatrick		Supported by 
13:30 – 14:00	Can cystic fibrosis patients finally catch a breath with cystic fibrosis transmembrane conductance regulator drugs? – 214 Dr Elena Schneider-Futschik, The University of Melbourne		
14:00 – 14:30	Understanding and informing medicines use among older Australians receiving residential aged care services – 215 Dr Janet Sluggett, Monash University		
14:30 – 15:00	Structure-function studies of drug metabolising enzymes: Application of computational approaches for the characterisation of structural plasticity and ligand recognition – 216 Dr Pramod Nair, Flinders University		
15:00 – 15:30	Pharmacoepidemiological studies in dementia: findings from Swedish national registers – 217 Dr Edwin Tan, Monash University		
15:30 – 15:55	Afternoon tea with exhibitors Pharmacoepidemiology SIG AGM Room: Hall M		Supported by  
16:00 – 17:00	ASCEPT Lecture Room: Hall M Chair: Prof Carl Kirkpatrick Continuing pain – the importance of collaboration – 218 Prof Andrew McLachlan, Sydney Pharmacy School, The University of Sydney		
17:00 – 18:00	ASCEPT AGM Room: Hall M		
19:00 – 23:00	Meeting dinner National Wine Centre of Australia, Corner Botanic and Hackney Roads		Supported by  

Friday 30 November 2018

08:00 – 15:45	Registration desk open Foyer, Hall L and M		
08:30 – 09:30	British Toxicology Society keynote address		
	Room: Hall M		Supported by  Bellberry Limited supporting research and ethics
	Chair: Prof Carl Kirkpatrick		
	Novel psychoactive substances – what’s happening out there and how do we know? – 300		
Dr John Thompson, School of Medicine, Cardiff University, UK			
09:30 – 10:05	Morning tea with exhibitors		
	Supported by  AUSTRALIAN MEDICINES HANDBOOK	Respiratory and Inflammation SIG AGM Room: L2	Drug Disposition and Response SIG AGM Room: L3
10:10 – 12:10	Symposium 7: Structural insights drive innovation in drug discovery and design	Symposium 8: Innovation in the treatment of depression	Oral presentations 7: Drug Disposition and Response/ Education
	Room: Hall M	Room: L2	Room: L3
	Chairs: Dr Andrew Keller and Dr David Thal	Chairs: Dr Daniel Barratt and Dr Bridin Murnion	Chairs: Assoc Prof David Foster and Dr Robyn Meech
10:10 – 10:25	The structural basis of class B G protein-coupled receptor activation and signaling – 301 Dr Denise Wootten, Monash Institute of Pharmaceutical Sciences, Monash University	Innovation in the treatment of depression: new insights into neuroimmune mechanisms of depression – 305 Dr Natalie Mills, The University of Adelaide	UGT2B11 and UGT2B28 have catalytic and non-catalytic functions and are dominant negative UGT regulators – 309 Dr Robyn Meech, Flinders University
10:25 – 10:40			Enabling drug development decisions through Model Informed Drug Development – 310 Dr Helen Kastrissios, Certara Strategic Consulting
10:40 – 10:55	Designing modulators of protein-protein interactions – 302 Dr Jess Holien, St Vincent’s Institute of Medical Research	Pharmacogenomics of antidepressants – current recommendations and pitfalls in clinical application – 306 Dr Dorothea Lesche, The University of Melbourne	Functional diversity of UDP-glucuronosyltransferase enzymes and novel modulation of nuclear receptor signaling – 311 Dr Julie-Ann Hulin, Flinders University
10:55 – 11:10			Population pharmacokinetics of colistin in paediatric patients: Implications for selection of dosage regimens – 312 Dr Cornelia Landersdorfer, Monash University
11:10 – 11:25	Discovery of first-in-class adenosine A1 receptor negative allosteric modulators by virtual ligand screening – 303 Dr Anh Nguyen, Monash Institute of Pharmaceutical Sciences, Monash University	Ketamine for treatment resistant depression – 307 Prof Andrew Somogyi, The University of Adelaide	Extracellular nanovesicle derived cytochrome P450 3A4 protein expression and activity – 313 Dr Andrew Rowland, Flinders University
11:25 – 11:40			Deregulation of ADME genes that are involved in drug absorption, distribution, metabolism, and excretion in hepatocellular carcinoma – 314 Dr Dong Gui Hu, Flinders University
11:40 – 11:55	Structural mechanism of partial agonists and antagonists of PPARgamma for use as antidiabetics – 304 Dr John Bruning, The University of Adelaide	Role of pharmacometrics and precision medicine in the treatment of depression – 308 Assoc Prof David Foster, The University of South Australia	PK Graph: A new freely available pharmacokinetic simulation application for medical education – 315 Dr Slade Matthews, University of Sydney
11:55 – 12:10			Deprescribing in the pharmacy curriculum: Feasibility and acceptability of a novel deprescribing workshop – 316 Dr Danijela Gnjidic, University of Sydney

12:10 – 13:15	Lunch with exhibitors and ASCEPT student poster finalists presentation		
	Diversity and inclusion workshop		<p>Supported by</p> 
	Room: Hall M		
	Chairs: Prof Carl Kirkpatrick and Dr Danijela Gnjidic		
	Presenter: Dr Darren Saunders, Science and Technology Australia		
Panel: Prof Rebecca Ritchie, Dr Sanam Mustafa, Assoc Prof Tina Hinton			
13:20 – 15:05	Oral presentations 8: Drug Discovery	Oral presentations 9: Pharmacoepidemiology	Oral presentations 10: Respiratory and Inflammation/ Urogenital and Gastrointestinal
	Room: Hall M	Room: L2	Room: L3
	Chairs: Prof Ross Bathgate and Dr Katie Leach	Chairs: Dr Jenni Ilomaki and Assoc Prof Kellie Charles	Chairs: Dr Stavros Selemidis and Prof Russ Chess-Williams
13:20 – 13:35	Structural insights into the activation of the adenosine A1 receptor – 317 Dr Christopher Draper-Joyce, Monash Institute of Pharmaceutical Sciences, Monash University	Systemic inflammation is associated with altered drug utilization in metastatic colorectal cancer patients – 324 Mr Madison Orr, The University of Sydney	Mechanism of human mast cell activation by polymyxins – 331 Miss Stephanie Zhang, The University of Melbourne
13:35 – 13:50	Exploring subtype differences in α1-adrenoceptor ligand residence time – 318 Miss Samantha Miles, University of New South Wales	Adherence and persistence to cholinesterase inhibitors: A longitudinal cohort study using dispensing records – 325 Ms Claire Keen, Monash University	Influenza A virus infection during pregnancy induces severe maternal vascular dysfunction and fetal growth restriction – 332 Dr Stella Liong, RMIT University
13:50 – 14:05	Probing the structural basis of mGlu5 allosteric agonism and biased signaling – 319 Dr Shane Hellyer, Monash Institute of Pharmaceutical Sciences, Monash University	Deprescribing in older inpatients: development of consumer information leaflets – 326 Ms Natali Jokanovic, The University of Sydney	Apocynin prevents hydrogen peroxide-induced atrophy in C2C12 skeletal muscle myotubes – 333 Miss Chanelle Mastronardo, RMIT University
14:05 – 14:20	The dynamics of ligand-GLP-1R-G protein coupling and its contribution to biased agonism – 320 Dr Elva Zhao, Monash Institute of Pharmaceutical Sciences, Monash University	Prevalence and incidence of prescription opioid analgesic use in Australia – 327 Ms Samanta Lalic, Monash University	Stiff cellular microenvironments promote the differentiation of human lung lipofibroblasts into (myo)fibroblasts – 334 Prof Alastair Stewart, The University of Melbourne
14:20 – 14:35	The receptor-effector interactions underpinning adenosine A2B receptor signal transduction – 321 Miss Bui San Thai, Monash Institute of Pharmaceutical Sciences, Monash University	MedicineInsight: National General Practice Prescribing Data – 328 Dr Bernie Mullin, NPS MedicineWise	Differential expression of thromboxane synthase in human colon; upregulation in Crohn's disease and with age – 335 Miss Lixin Zhang, University of New South Wales
14:35 – 14:50	Dysregulation of the actin cytoskeleton by ω-3 tolyl-urea fatty acid - a novel inhibitor of breast cancer cell migration – 322 Mr Yassir Al-zubaidi, The University of Sydney	Treatment initiation for Type 2 Diabetes in Australia: Are the guidelines being followed? – 329 Mr Stephen Wood, Monash University	Serelaxin enhances the renoprotective effects of human amnion epithelial cell-derived exosomes in a murine model of obstructive nephropathy – 336 Mr Matthew Shen, Monash University
14:50 – 15:05	Dimethylarginine dimethylaminohydrolase-1 (DDAH1) inhibition as a novel therapeutic strategy in cancer types associated with excessive nitric oxide synthesis – 323 Dr Sara Tommasi, Flinders University	The 'Talking about deprescribing' resource to facilitate conversations about medicines discontinuation in residential aged care – 330 Ms Leonie Picton, Monash University	Mechanisms underlying purinergic P2X7 receptor antagonism in maintaining urothelial barrier function against acrolein-induced inflammation and cytotoxicity – 337 Miss Zhinoos Taidi, University of New South Wales
15:05 – 15:15	Comfort break		
15:15 – 15:45	Awards and meeting close		
	Room: Hall M		
	Chair: Prof Carl Kirkpatrick		